Back to News
Market Impact: 0.2
16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage
Source: 247wallst.com
Healthcare & BiotechCorporate EarningsCompany Fundamentals
Employers are reconsidering who pays for GLP-1 weight-loss drugs, with potentially different implications for Eli Lilly and Novo Nordisk ahead of earnings week. The article provides no figures or details on the expected impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Fed chairman talks tough on inflation — plus, what's behind Micron's big rally
- Nasdaq-100 futures dip as Alphabet shares sell off after earnings report: Live updates
- Waters’ new AI tool targets one of the pharmaceutical industry’s most tedious tasks
- Jim Cramer sees buying opportunities in these 2 beaten-down stocks
- Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
- Bloomberg Law: Parents Demand Justice & Copycat Drugs (Podcasts)